| NCT ID | NCT07572773 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jill Kolesar |
| Condition | Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2026-06-12 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2026-06-12 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose CT for adults aged 50-80 with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years. Despite insurance coverage, only 17% of eligible Iowans were screened in 2024. Barriers include the complexity of screening and competing demands in primary care. To address these challenges, investigators propose a two-part intervention: a blood-based screening test to simplify LCS and a community pharmacist-led referral program integrated into routine pharmacy care. Eligible patients will be identified at Greenwood Pharmacy in Waterloo, Iowa. Interested individuals will be consented by a pharmacist and engaged in shared decision-making about LCS. Participants may decline screening, complete the DELFI Diagnostics FirstLook lung cancer screening blood test, or pursue CT screening through their primary care physician. Those choosing the blood test will be referred to Cedar Valley Family Medicine. Patients with a positive result will complete a standard shared decision-making visit with their PCP and, if appropriate, undergo confirmatory CT imaging. Patients with a negative result will enter a screening cohort and be re-screened annually for an additional year.
Eligibility Criteria
Inclusion Criteria: * aged 50-77 * smoking pack-year history of ≥ 20 years * current smoker or quit smoking 15 or less years ago * ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * self-report of lung cancer screening in the last 12 months * psychiatric illness/social situations that would limit compliance with study requirements
Contact & Investigator
Jill Kolesar, PharmD, MS, FCCP
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT07572773 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 77 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07572773 currently recruiting?
Yes, NCT07572773 is actively recruiting participants. Contact the research team at champ-study@uiowa.edu for enrollment information.
Where is the NCT07572773 trial being conducted?
This trial is being conducted at Iowa City, United States, Waterloo, United States, Waterloo, United States.
Who is sponsoring the NCT07572773 clinical trial?
NCT07572773 is sponsored by Jill Kolesar. The principal investigator is Jill Kolesar, PharmD, MS, FCCP at University of Iowa. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.